DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Marketable Securities

Note 4 - Marketable Securities

3 Months Ended

Mar. 31, 2021

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

4.	Marketable Securities

The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):

	Fair Value Measurements Using Inputs Considered as of:
	March 31, 2021								December 31, 2020
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Government securities	$	6,004	$	—	$	6,004	$	—	$	8,924	$	—	$	8,924	$	—
Bank certificates of deposit		245		—		245		—		496		—		496		—
Commercial paper and corporate bonds		13,823		—		13,823		—		10,678		—		10,678		—
Total	$	20,072	$	—	$	20,072	$	—	$	20,098	$	—	$	20,098	$	—

Accrued interest receivable on available-for-sale securities is included in amounts receivable and was

$37,000

and

$34,000

as of

March 31, 2021

and

December 31, 2020,

respectively.

There were

transfers of assets between Level

and Level

of the fair value measurement hierarchy during the

three

months ended

March 31, 2021.

Under the terms of the Company's investment policy, purchases of marketable securities are limited to investment grade governmental and corporate obligations and bank certificates of deposit with a primary objective of principal preservation. Maturities of individual securities are less than

one

year and the amortized cost of all securities approximated fair value as of

March 31, 2021

and

December 31, 2020.